Nordic | Biotech & Healthcare Your insights to listed Danish & Nordic biotech & healthcare stocks. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc. We also present the top 3 best-performing stocks in the Nordics each week.

The past week was full of news (again); Ascendis Pharma announced a big deal with Teijin in Japan, Epxres2ion received a grant of 8MEUR, Genmab presented a regulatory update for Epcoritamab, Scandion Oncology received a patent to its lead-candidate and Gubra announced first dosed patient in a phase 1 trial.

13 of the 20 listed Danish biotech companies published news. 9 of the 20 companies had a positive share price development the past week and 9 companies have had a positive share price performance year-to-date. Cessatech continues to be the best performing stock year-to-date with a 166% increase.

---

Do you want to stay tuned to the developments of impact companies and stocks in the Nordics? Then we have something for you! We have launched a brand new blog and newsletter that dives into impact stocks listed in the Nordics. The newsletter help you to invest more sustainably in the businesses of tomorrow, track the development of multiple sectors including energy production, waste management, and carbon capture, and follow the developments of over 100 large, medium and small cap companies.

---

Danish Company news the past week

Ascendis Pharma

Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan (Link)

Biosergen

 Biosergen publishes interim report for third quarter 2023 (Link)

Cessatech

No news the past week

CS Medica

CS Medica postpones its Annual Report to February 24, 2024 and the Annual General Meeting to February 29, 2024 (Link)

Curasight

No news the past week

Evaxion Biotech

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept (Link)

ExpreS2ion

ExpreS2ion announces new EU-funded Horizon Europe grant award for Nipah virus vaccine development (Link)

Fluoguide

FluoGuide A/S publishes interim report for the period January – September 2023 (Link)

Genmab

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma (Link)

Jeffries lowered their price target from 2900 DKK to 2400 DKK

Gubra

Gubra announces first subject dosed in Phase 1 clinical trial of amylin agonist (GUBamy) for the treatment of obesity (Link)

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

Pila Pharmas ongoing rights issue ends on monday December 4 2023 (Link)

Saniona

Saniona publishes its interim report for the third quarter of 2023 (Link)

Scandion Oncology

Scandion Oncology is granted new Composition of Matter-patent on lead compound SCO-101 extending its exclusivity until at least 2042 (Link)

SynAct Pharma

No news the past week

ViroGates

The subscription period in ViroGates’ rights issue began on 30 November (Link)

Zealand Pharma

Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers (Link)

Danske Bank raised their price target on Zealand Pharma from 350 DKK to 400 DKK

Y-mAbs Therapeutics

No news the past week

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a positive share price performance last week of 1.6%. Expres2ion Biotech rose 46% after they got a grant from the EU-funded Horizon Europe of 8 MEUR corrosponding to 90 MSEK. Ascendis Pharma also did well with a 13% increase following a partnership with Teijin Limited in Japan for development and commericalization of TransCon in Japan. Ascendis Pharma will recieve 70 MUSD in upfront payments, up to 175 MUSD in milestone payments as well as royalties in the mid-20’s. Furthermore, Genmab presented a regulatory update for Epcoritamab, while Scandion Oncology got a patent on its lead candidate and Gubra announced first dosed patient in a phase 1 trial. The three best stocks year-to-date are Curasight, Cessatech, and Saniona with performances of 86-166%. Overall, the Danish biotech and healthcare stocks are in negative territory this year with a year-to-date return of -2.8%.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date and last twelve months

Nordic biotech and healthcare developments (KPHC-index)

In the past week, the Kapital Partner Nordic Healthcare Index (KPHC) fell 0,3% to 61.61 and thus a small drawback after weeks of improvements. Kapital Partner Nordic Healthcare Index tracks all biotech & healthcare companies in the Nordics. It includes large-cap companies such as Novo Nordisk and Genmab as well as smaller companies such as Curasight. In the past 12 months, it has significantly underperformed relative to the C25-index in Copenhagen and S30-index in Stockholm, while the Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC-index’s downward trajectory.

The index development for Kapital Partner Healthcare Index the past 12 months

46-160% in weekly retrun for the three best performing Nordic biotech & healthcare stocks the past week

Promore Pharma AB (160%) (Nordnet) is a Swedish biopharmaceutical company. In the past week, they announced a reverse acquisition of PMD Device Solutions AB (read more).

QuiaPEG Pharmaceuticals Holding AB (70%) (Nordnet)  operates in medical technology. The company has developed a technological platform that is used to develop existing pharmaceuticals. The technology is based on what is known as PEGylation, a technique that connects water-soluble polymers with the pharmaceuticals and is used to improve various characteristics in the biopharmaceuticals in regards to stability and resistance.

Expres2ion Biotech Holding AB (46%) (Nordnet) is a research and development-based company with a patented platform in biotech protein production. The company has its own development pipeline of vaccine candidates for COVID-19, breast cancer, influenza, and malaria. In addition, the company generates revenue from the sale of manufacturing services and platform licenses. In the past week, Expres2ion got a 8 MEUR grant for the development of a vaccine against Nipah virus (read more).

Sources: Refinitiv & Nordnet